UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 279

Sortiert nach

Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B

EClinicalMedicine, 2024-08, Vol.74, p.102733, Article 102733

2024

Volltextzugriff (PDF)

Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part BResearch in context

EClinicalMedicine, 2024-08, Vol.74, p.102733

2024

Volltextzugriff (PDF)

C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement

Molecular therapy, 2024-04, Vol.32 (4), p.1061-1079

2024

Volltextzugriff (PDF)

Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study

Blood, 2024-02, Vol.143 (8), p.713

2024

Volltextzugriff (PDF)

Toxigenic Clostridium perfringens isolated from at-risk pediatric inflammatory bowel disease patients

Journal of Crohn's and colitis, 2024-01, Vol.18 (7), p.985-1001

2024

Volltextzugriff (PDF)

Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy

Bone marrow transplantation (Basingstoke), 2024-01, Vol.59 (1), p.52-58

2024

Volltextzugriff (PDF)

Inhibitors targeting BamA in gram-negative bacteria

Biochimica et biophysica acta. Molecular cell research, 2024-01, Vol.1871 (1), p.119609-119609, Article 119609

2024

Volltextzugriff (PDF)

Esophageal motility in systemic sclerosis before and after autologous hematopoietic cell transplantation

Clinical rheumatology, 2023-12, Vol.42 (12), p.3267-3274

2023

Volltextzugriff (PDF)

The cancer-associated glycan polysialic acid is dysregulated in systemic sclerosis and is associated with fibrosis

Journal of autoimmunity, 2023-11, Vol.140, p.103110-103110, Article 103110

2023

Volltextzugriff (PDF)

26 Sustained complement C1s inhibition with sutimlimab in patients with cold agglutinin disease results in continued efficacy during part B of the randomized placebo-controlled phase 3 CADENZA study (NCT03347422)

Immunobiology (1979), 2023-09, Vol.228 (5), p.152483, Article 152483

2023

Volltextzugriff (PDF)

P1471: SUSTAINED EFFICACY OF SUTIMLIMAB, A COMPLEMENT C1S INHIBITOR, IN PATIENTS WITH COLD AGGLUTININ DISEASE: RESULTS FROM PART B OF THE PHASE 3 CADENZA STUDY

HemaSphere, 2023-08, Vol.7 (S3), p.e83270db-n/a

2023

Volltextzugriff (PDF)

P1469: INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): RESULTS FOLLOWING 9‐WEEK OFF‐TREATMENT PERIOD (WASHOUT) IN THE PHASE 3 CADENZA STUDY

HemaSphere, 2023-08, Vol.7 (S3), p.e3331235-n/a

2023

Volltextzugriff (PDF)

Structure-Based Design of Promysalin Analogues to Overcome Mechanisms of Bacterial Resistance

ACS omega, 2023-04, Vol.8 (13), p.12558-12564

2023

Volltextzugriff (PDF)

Donor Genetic Predisposition to High Interleukin-10 Production Appears Protective against Acute Graft-Versus-Host Disease

International journal of molecular sciences, 2022-12, Vol.23 (24), p.15888

2022

Volltextzugriff (PDF)

Incomplete chimerism following myeloablative and anti-thymocyte globulin-conditioned hematopoietic cell transplantation is a risk factor for relapse and chronic graft-versus-host disease

Cytotherapy (Oxford, England), 2022-12, Vol.24 (12), p.1225-1231

2022

Volltextzugriff (PDF)

Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)

Blood, 2022-11, Vol.140 (Supplement 1), p.2825-2827

2022

Volltextzugriff (PDF)

Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy

Rheumatology (Oxford, England), 2022-10, Vol.61 (10), p.4155-4162

2022

Volltextzugriff (PDF)

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial

Blood, 2022-09, Vol.140 (9), p.980-991

2022

Volltextzugriff (PDF)

P1339: CLINICAL OUTCOMES OF PATIENTS WITH EBV+ PTLD FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION WHO FAIL RITUXIMAB: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY

HemaSphere, 2022-06, Vol.6 (Suppl), p.1224-1225

2022

Volltextzugriff (PDF)

Development and Optimization of Bifunctional Fusion Proteins to Locally Modulate Complement Activation in Diseased Tissue

Frontiers in immunology, 2022-06, Vol.13, p.869725-869725

2022

Volltextzugriff (PDF)

Classical Complement Pathway Inhibition in a “Human‐On‐A‐Chip” Model of Autoimmune Demyelinating Neuropathies

Advanced therapeutics, 2022-06, Vol.5 (6), p.n/a

2022

Volltextzugriff (PDF)

Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation

Cytotherapy (Oxford, England), 2022-04, Vol.24 (4), p.413-420

2022

Volltextzugriff (PDF)

Mild clinical course of SARS-coronavirus-2 infection early posttransplant in patients with adoptively transferred antibody response

Bone marrow transplantation (Basingstoke), 2022-01, Vol.57 (1), p.119-121

2022

Volltextzugriff (PDF)

Inhibition of Complement C1s By Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Efficacy and Safety Results from the Randomized, Placebo-Controlled Phase 3 CADENZA Study

Blood, 2021-11, Vol.138 (Supplement 1), p.349-349

2021

Volltextzugriff (PDF)

Chimerism of Blood T-Cells and Leukemia Lineage Cells Following Myeloablative Hematopoietic Cell Transplantation Is a Risk Factor for Relapse and Chronic Graft-Versus-Host Disease

Blood, 2021-11, Vol.138 (Supplement 1), p.4887-4887

2021

Volltextzugriff (PDF)

1 – 25 von 279

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(206)
Mit Volltextzugriff
(264)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(142)
Life Sciences & Biomedicine
(128)
Humans
(109)
Hematology
(77)
Adult
(68)
Male
(67)
Female
(65)
Middle Aged
(64)
Immunology
(62)
Transplantation
(58)
Biological And Medical Sciences
(41)
Hematology, Oncology And Palliative Medicine
(39)
Medical Sciences
(39)
Adolescent
(37)
Aged
(36)
Hematopoietic Stem Cell Transplantation
(30)
Stem Cell Transplantation
(28)
Anesthesia. Intensive Care Medicine. Transfusions. Cell Therapy And Gene Therapy
(25)
Animals
(25)
Hematopoietic Stem Cell Transplantation - Methods
(25)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B

Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part BResearch in context

C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement

Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study

Toxigenic Clostridium perfringens isolated from at-risk pediatric inflammatory bowel disease patients

Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy

Inhibitors targeting BamA in gram-negative bacteria

Esophageal motility in systemic sclerosis before and after autologous hematopoietic cell transplantation

The cancer-associated glycan polysialic acid is dysregulated in systemic sclerosis and is associated with fibrosis

26 Sustained complement C1s inhibition with sutimlimab in patients with cold agglutinin disease results in continued efficacy during part B of the randomized placebo-controlled phase 3 CADENZA study (NCT03347422)

P1471: SUSTAINED EFFICACY OF SUTIMLIMAB, A COMPLEMENT C1S INHIBITOR, IN PATIENTS WITH COLD AGGLUTININ DISEASE: RESULTS FROM PART B OF THE PHASE 3 CADENZA STUDY

P1469: INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): RESULTS FOLLOWING 9‐WEEK OFF‐TREATMENT PERIOD (WASHOUT) IN THE PHASE 3 CADENZA STUDY

Structure-Based Design of Promysalin Analogues to Overcome Mechanisms of Bacterial Resistance

Donor Genetic Predisposition to High Interleukin-10 Production Appears Protective against Acute Graft-Versus-Host Disease

Incomplete chimerism following myeloablative and anti-thymocyte globulin-conditioned hematopoietic cell transplantation is a risk factor for relapse and chronic graft-versus-host disease

Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)

Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial

P1339: CLINICAL OUTCOMES OF PATIENTS WITH EBV+ PTLD FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION WHO FAIL RITUXIMAB: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY

Development and Optimization of Bifunctional Fusion Proteins to Locally Modulate Complement Activation in Diseased Tissue

Classical Complement Pathway Inhibition in a “Human‐On‐A‐Chip” Model of Autoimmune Demyelinating Neuropathies

Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation

Mild clinical course of SARS-coronavirus-2 infection early posttransplant in patients with adoptively transferred antibody response

Inhibition of Complement C1s By Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Efficacy and Safety Results from the Randomized, Placebo-Controlled Phase 3 CADENZA Study

Chimerism of Blood T-Cells and Leukemia Lineage Cells Following Myeloablative Hematopoietic Cell Transplantation Is a Risk Factor for Relapse and Chronic Graft-Versus-Host Disease

Suchergebnisse filtern